This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Genentech Reports Profit Rise

Genentech (DNA) delivered a 1-cent earnings beat for the third quarter and surpassed expectations with sales of cancer-drug Avastin Monday. Sales of other products, however, fell shy of consensus targets, realizing recent analyst predictions following the release of soft prescription data.

The company reported earning 73 cents a share, or $778 million, before items, compared to 59 cents a share, or $637 million, in 2006.

Analysts surveyed by Thomson financial were looking for 72 cents a share on revenue of $2.93 billion. Genentech reported revenue of $2.91 billion before items (and including $3 million associated with the acquisition of Tanox), a 22% increase over operating revenue of $2.38 billion in the third quarter of 2006.

Despite the dose reduction in Avastin, the company beat the consensus target of $586 million, reporting sales of $597 million, compared to $435 million in the year-ago quarter. It also surpassed Street expectations of $585 million.

Genentech was expected to miss targets at least slightly for Rituxan, for non-Hodgkin's lymphoma and as a combination therapy for rheumatoid arthritis, and Lucentis, for wet-age related macular degeneration (AMD), on the basis of recent prescription data. The consensus was $588 million and $210 million, respectively. The company reported Rituxan sales of $572 million, compared to $509 million in the year-ago quarter, and Lucentis sales of $198 million, compared to $153 million in the same quarter in 2006.

Sales of breast cancer treatment Herceptin were $320 million, compared to $302 million in the year-ago quarter, and falling short of the consensus target of $339 million. Sales of Tarceva were $101 million compared to $100 million in 2006, and also falling shy of the Wall Street consensus of $111 million.

Genentech reaffirmed previous non-GAAP earnings guidance for fiscal 2007 of $2.85 to $2.95 a share, a 28%-32% increase in comparison to 2006. The consensus target is on the high end of that, at $2.95.

Shares were falling $1.13, or 1.5%, to $76.37 in after-hours trading.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs